Article
A bispecific antibody overcomes limitations of prior strategies to achieve effective and…
medRxiv · 2025 · Goldmacher, V. S.; Gershteyn, I. M.; Chari, R.; Kovtun, Y.
Key facts
| Title | A bispecific antibody overcomes limitations of prior strategies to achieve effective and tumor-selective Death Receptor 5 (DR5) clustering |
|---|---|
| First author | Goldmacher, V. S.; Gershteyn, I. M.; Chari, R.; Kovtun, Y. |
| Journal | medRxiv |
| Published | Jan 1, 2025 |
| DOI | 10.1101/2025.01.10.632444 |
| Devices mentioned | K912666 |
| Product codes mentioned | LIQ |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1